Axogen (AXGN) just cleared a major regulatory hurdle, securing FDA approval for Avance as the first biologic therapeutic for peripheral nerve repair. The company also received 12 years of market exclusivity and issued new 2026 sales guidance.

The FDA approval, upsized equity raise and new 2026 guidance come after a period of mixed trading, with a 1-day share price return of 2.18% and a 90-day share price return of 11.34%, while the 1-year total shareholder return of 64.18% points to stronger longer term momentum.

If this regulatory milestone has you looking beyond a single name, it could be a good time to broaden your research with our 29 healthcare AI stocks as potential next ideas to review.

Axogen now trades around $31.90, with the share price still below the average analyst target and only a small estimated intrinsic discount. With FDA approval, cash in the bank and fresh guidance, is there still a buying opportunity here, or is the market already pricing in future growth?

Most Popular Narrative: 14.6% Undervalued

Axogen's most followed narrative points to a fair value of about $37.33, which sits above the latest close of $31.90 and frames this approval in a tighter valuation band.

Broad-based adoption of Axogen's nerve care algorithm across multiple markets (extremities, oral maxillofacial, breast) and exceptional momentum in activating high-potential accounts signal that the addressable market for nerve repair is still substantially underpenetrated, suggesting a long runway for sustained double-digit revenue growth as awareness and adoption rise.

Curious what revenue growth arc, future margins and valuation multiple have to look like to support that fair value gap? The narrative leans on ambitious scaling, improving profitability and a rich future earnings multiple to get there, but the exact mix of assumptions might surprise you.

Result: Fair Value of $37.33 (UNDERVALUED)

However, this hinges on Axogen managing its heavy dependence on Avance Nerve Graft while also avoiding reimbursement or competitive pressures that could cap future procedure volumes.

Another Way to Look at Valuation

That 14.6% discount to fair value from the narrative sits awkwardly next to the current P/S ratio of 7.4x. The fair ratio is 4x, the US Medical Equipment industry sits around 2.9x and peers average 4.9x, which points to richer pricing and higher valuation risk if expectations ease.

Next Steps

If the mix of optimism and caution here feels finely balanced, now is a good moment to review the numbers yourself and pressure test the thesis. A helpful place to start is by weighing up the 3 key rewards and 2 important warning signs that stand out most for you.

Ready for more investment ideas?

If this got you thinking harder about where your next edge might come from, do not stop here. The screener can quickly surface other opportunities worth your attention.

• Spot potential value plays by checking companies that currently appear mispriced on fundamentals with our 53 high quality undervalued stocks.
• Prioritise resilience by scanning for businesses with strong finances and cleaner balance sheets using the solid balance sheet and fundamentals stocks screener (41 results).
• Hunt for under-the-radar opportunities before they are widely talked about through the screener containing 24 high quality undiscovered gems.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.